Clinical trial
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed…
NCT00481247 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00481247 |
|---|---|
| Title | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia |
| Official title | An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia |
| Acronym | DASISION |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Chronic |
| Intervention type | Drug |
| Interventions | Dasatinib, Imatinib |
| Enrollment | 547 |
| Start date | Sep 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2015 |
| First posted | Jun 1, 2007 |
| Last update posted | Feb 15, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Chile, China, Colombia, Czechia, Denmark, France, Germany and 15 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: